Laurus Labs is a research-driven pharmaceutical company built on the idea that complex chemistry, done at scale, can make life-saving medicines affordable worldwide. Founded in 2005 by Dr. Satyanarayana Chava, it began as a single-product supplier of anti-HIV drug ingredients and has since expanded into a full-spectrum, vertically integrated player - controlling everything from raw-material sourcing to finished tablets - while adding biotechnology and cell therapy capabilities. The recurring approach is to invest in large-scale manufacturing capacity and deep scientific expertise ahead of demand, then apply a single quality standard whether the customer is a Big Pharma innovator, a US generics buyer, or a global health programme in Africa.
Business segments
Three engines at different stages - a generics cash cow that supplies one in three HIV patients globally, a fast-growing contract development and manufacturing arm serving Big Pharma, and an early-stage cell-and-gene-therapy bet - each built on the same large-scale chemistry and biotech backbone.
1. Affordable Medicines: the volume engine that makes generics at global scale
This division makes the active ingredients and finished pills that treat HIV, heart disease, diabetes and more - and it supplies one-third of the world’s HIV patients through tender-driven institutional contracts.
- Backward integration locks in cost advantage - the company makes its own starting materials, intermediates and APIs (active pharmaceutical ingredients), then uses those APIs in its own finished tablets, so it captures margin at every step rather than buying from a middleman.
- The ARV franchise is a global pillar - antiretroviral (ARV) drugs for HIV treatment generated 41% of total company revenue in FY26, with a 25-30% share of the donor-funded low- and middle-income country market and over 90% share of demand for the key drug Dolutegravir.
- APIs are sold to almost every major generics player - the company supplies active ingredients to nine of the ten largest generic pharmaceutical companies globally, and to 80% of the firms that bid for ARV tenders, making it a critical supplier even to its own formulation competitors.
- The business has deliberately reduced its ARV dependence - ARV revenue share has fallen from 67% in FY19 to 41% in FY26 as the company diversified into oncology, cardiovascular, CNS and diabetes therapies, de-risking the portfolio from tender cycles and pricing pressure.
2. CDMO: the innovation partner for Big Pharma and biotech
This division develops and manufactures complex drug molecules on contract for innovator companies - from early lab work through to commercial supply - and is the company’s main growth bet.
- A pipeline of over 125 projects spans human and animal health - the small-molecules CDMO business works on new chemical entities for human health (about 102 projects), animal health and crop science (around 23 projects), earning revenue through fee-for-service contracts at every stage from clinical development to commercial manufacturing.
- Technology platforms handle chemistry most rivals cannot - proprietary capabilities in continuous flow chemistry, biocatalysis (enzyme-driven reactions), high-potent chemistry and spray drying let the company tackle 10-12 step syntheses that combine multiple advanced techniques, which makes it a one-stop shop for innovator customers.
- Animal health is a dedicated, near-full factory - a purpose-built facility for animal health drug substances, commissioned in November 2023, handles steroids, hormones and high protein molecules, and its capacity is almost fully contracted with one Big Pharma partner.
- The Bio division adds fermentation to the toolkit - Laurus Bio uses precision fermentation and recombinant DNA technology to make ultra-pure, animal-origin-free ingredients for biopharma customers, and also serves over 80 clients with recombinant proteins for food, nutrition and personal care.
- China-plus-one sourcing is a structural tailwind - as Big Pharma diversifies its vendor base away from China, the company benefits because it is already an approved supplier to more than seven Big Pharma clients, making onboarding for new projects faster than starting from scratch.
3. Cell and Gene Therapy: a long-shot bet on one-time cures
Through its associate company ImmunoACT, Laurus has a stake in India’s first homegrown CAR-T cell therapy - a treatment that engineers a patient’s own immune cells to fight cancer - and is building the infrastructure to manufacture these therapies at scale.
- Manufacturing capacity has increased threefold - a second GMP facility spanning over 50,000 square feet was commissioned in March 2026, lifting total capacity from about 600 to roughly 3,100 treatments per year, which is critical because each dose is made individually from a patient’s own T-cells.
- The therapy is reaching patients through a growing hospital network - NexCAR19 is available in more than 60 hospitals across India, and a partnership with Cipla will extend its reach into Africa.
- Laurus is also building the upstream capabilities for advanced biologics - a process development lab for antibody-drug conjugates (ADCs) and gene therapy is operational in Hyderabad, and a cGMP facility is under construction, positioning the company to serve the next wave of cell and gene therapy manufacturing.
Group structure and partners
The company operates through a listed parent with a web of subsidiaries and joint ventures that separate its CDMO, biotech and renewable-energy activities, while a restructuring is underway to simplify the structure.
- A composite scheme will fold the CDMO subsidiary into the parent - Laurus Synthesis Private Limited (LSPL), the wholly-owned CDMO unit, will have one manufacturing unit demerged into Sriam Labs and the rest amalgamated into Laurus Labs Ltd, dissolving LSPL with effect from April 2026.
- Laurus Bio has brought in external investors - the biotech subsidiary, originally acquired as Richcore Lifesciences in 2021, sold a 13.73% stake to Eight Roads Ventures and F-Prime Capital for ₹120 crore, while Laurus Labs retains a 74.64% holding on a fully diluted basis following the initial investment, which increased to 75.61% after a subsequent additional investment.
- A joint venture with Krka targets new finished-dose markets - the 51:49 JV with Slovenian generics firm Krka is building a cGMP formulations facility on a 19-acre site in Hyderabad, with Phase 1 expected by mid-2027 and a combined investment of up to €50 million.
- Renewable-energy associates cut power costs - Laurus holds a 26% stake in two renewable-energy entities, giving it captive access to a 10 MW solar plant and 25.53 MW of combined wind and solar capacity, which feeds its energy-intensive manufacturing sites.
- Academic and global-health partnerships supply the pipeline - in-licensed gene therapy assets from IIT Kanpur, a long-standing Medicines Patent Pool licence for HIV drugs, and a CHAI-Unitaid collaboration on a paediatric HIV formulation all extend the company’s R&D reach without requiring it to invent everything in-house.